Press Releases

Date

Title

08 Mar 2021
Mainstay Medical Announces Commercial Launch of ReActiv8 in Australia
16 Feb 2021
Mainstay Medical Announces US$108 Million Equity Financing Transaction
25 Jan 2021
Mainstay Medical Announces Key Strategic Hires to Drive Global Commercial Expansion
28 Jul 2020
Mainstay Medical to Present at the LifeSci Partners Summer Symposium
22 Jun 2020
Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain
09 Jun 2020
Mainstay Medical Announces Reimbursement Approval for ReActiv8 in Australia
05 Jun 2020
Mainstay Medical announces Scheme becoming effective
04 Jun 2020
Receipt of High Court approval in connection with proposed Reorganisation
02 Jun 2020
Mainstay Medical announces expected timetable for completion of Reorganisation
28 May 2020
Mainstay Medical announces Date for Court Hearing
11 May 2020
Mainstay Medical announces Results of Scheme Meeting and EGM
15 Apr 2020
Mainstay Medical announces publication and posting of Circular related to proposed Reorganization
07 Apr 2020
Mainstay Medical announces strategic plans to maximize shareholder value, including proposals to establish new holding company and delist its Shares from Euronext Growth and Euronext Paris
25 Feb 2020
Mainstay Releases 2019 Annual Report
11 Dec 2019
Mainstay Medical Announces Completion of Day 100 Meeting with FDA Regarding Pre-Market Approval (PMA) Application for ReActiv8
06 Dec 2019
Mainstay Medical Announces Regulatory Approval from Australian Therapeutic Goods Administration (TGA) for ReActiv8
25 Oct 2019
Mainstay Medical Announce Publication of Prospectus and Admission
01 Oct 2019
Mainstay Medical Announces Acceptance For Filing by US FDA Of Pre-Market Approval (PMA) Application for ReActiv8
20 Sep 2019
Mainstay Medical Announces 2019 Half Year Financial Results Conference call – Friday, 20 September 2019 at 13:00 BST
12 Sep 2019
Mainstay Medical Announces Date for 2019 Half Year Results
30 Jul 2019
Mainstay Medical Announces Completion of Financing Transactions
26 Jun 2019
Mainstay Medical Announces Completion of Pre-Submission Meeting with FDA Regarding Pre-Market Approval (PMA) Application for ReActiv8
19 Apr 2019
Mainstay Releases 2018 Annual Report
03 Dec 2018
Mainstay Medical to Showcase ReActiv8 and Key Clinical Data at the 13th German Spine Congress of the DWG
21 Nov 2018
Mainstay Medical Announces Participation in 30th Annual Piper Jaffray Healthcare Conference
19 Nov 2018
Mainstay Medical Announces Headline Results from ReActiv8-B Clinical Study Conference Call and Webcast – 19 November 2018, 8am GMT/ 9am CET
19 Nov 2018
ReActiv8-B Results Presentation for Conference Call and Webcast – 19 November 2018
24 Sep 2018
Mainstay Medical Announces Board Change
21 Sep 2018
Mainstay Medical Announces 2018 Half Year Financial Results Conference call – Friday, 21 September 2018 at 13:00 GMT
04 Sep 2018
Mainstay Medical Announces Date for 2018 Half Year Results
20 Aug 2018
Mainstay Medical Announces the Appointment of Matthew Onaitis as Chief Financial Officer
09 Jul 2018
Mainstay Medical announces the completion of all implants in the ReActiv8-B Study
20 Jun 2018
Mainstay Medical Appoints Wolfgang Frisch as VP and Managing Director for Germany
22 May 2018
Mainstay Medical Announces CFO Transition
04 May 2018
Mainstay Medical Announces Publication of Prospectus and Admission
05 Apr 2018
Update on Regulatory Application for ReActiv8 in Australia
15 Feb 2018
Mainstay Medical Announces €30 million Financing
15 Feb 2018
Mainstay Releases 2017 Annual Report
23 Jan 2018
Mainstay confirms its continued eligibility to the PEA-PME
11 Dec 2017
Mainstay Medical Announces Positive Outcome of Interim Analysis
09 Oct 2017
Mainstay Medical Announces Jason Hannon Joins Board of Directors
05 Sep 2017
Mainstay Medical Announces CEO Leadership Transition
05 Sep 2017
Mainstay Medical Announces 2017 Half Year Financial Results
04 Sep 2017
Mainstay Medical Announces Date for 2017 Half Year Results
03 Aug 2017
Mainstay Medical’s ReActiv8-B Clinical Trial Passes Mid-point
22 Jun 2017
Mainstay Medical to Host Key Opinion Leader Event on the Chronic Low Back Pain Treatment Landscape Webcast – Monday, 26 June 2017 at 12.00pm EDT
15 Jun 2017
Mainstay Medical to Present at the JMP Securities 2017 Life Sciences Conference Webcast – Tuesday, 20 June 2017 at 10.30am EDT
31 May 2017
Mainstay Medical to Present at the Jefferies 2017 Global Healthcare Conference
16 May 2017
Mainstay Medical to Present at the UBS Global Healthcare Conference
09 May 2017
Mainstay Medical Starts Commercialization of ReActiv8® for the Treatment of Chronic Low Back Pain in Ireland
28 Apr 2017
Mainstay Medical to Present at the Deutsche Bank 42nd Annual Health Care Conference
19 Apr 2017
Mainstay Medical to Present at the MedTech Strategist Innovation Summit: Dublin 2017
31 Mar 2017
Mainstay Medical to Present at the 24th MedTech Investing Europe Conference
23 Mar 2017
Mainstay Medical Publishes 2016 Full Year Results and Business Update Conference call – Thursday, 23 March 2017 at 12:30 pm GMT
16 Mar 2017
Mainstay Medical Announces Date for 2016 Full Year Results
07 Mar 2017
Mainstay Medical to Present at the Canaccord Genuity 2017 Musculoskeletal Conference
02 Feb 2017
Mainstay Medical to Present at the 3rd annual Biotech and Money / Medtech and Money London Conference
01 Feb 2017
Mainstay Medical Starts Commercialization of ReActiv8® for the Treatment of Chronic Low Back Pain
24 Jan 2017
Mainstay confirms its continued eligibility to the PEA-PME
12 Jan 2017
Mainstay Medical Applies for Approval to Market ReActiv8® in Australia
06 Jan 2017
Mainstay Medical to Present at Medtech Showcase 2017
27 Oct 2016
Mainstay Medical to Attend ‘Actionaria’ in Paris, a leading tradeshow in Europe dedicated to individual investors
26 Oct 2016
Mainstay Medical Announces Additional U.S. Patent Issued
06 Oct 2016
First Subject Implanted in Mainstay Medical’s ReActiv8-B Clinical Trial for Treatment of Chronic Low Back Pain
22 Sep 2016
Mainstay Medical Announces 2016 Half Year Financial Results
20 Sep 2016
ReActiv8-A Clinical Trial – Sustained Performance at One Year
16 Sep 2016
Mainstay Medical to Present at the Ladenburg Thalmann 2016 Healthcare Conference and the Sachs Associates 4th Annual Medtech & Digital Health Forum
14 Sep 2016
Mainstay Medical’s ReActiv8-B Clinical Trial for Treatment of Chronic Low Back Pain Enrolls First Subject
12 Sep 2016
Mainstay Medical Announces Date for 2016 Half Year Results
11 Aug 2016
Mainstay Medical Announces Publication of Prospectus and Admission
11 Aug 2016
Mainstay Medical to Present at Wedbush PacGrow 2016 Healthcare Conference
20 Jun 2016
Mainstay Medical to present at the 2016 JMP Securities Life Sciences Conference
17 Jun 2016
Mainstay Medical Announces €30 million Fundraising
25 May 2016
Mainstay Medical Achieves CE Marking for ReActiv8®
28 Apr 2016
Mainstay Medical Publishes its 2015 Annual Report
27 Apr 2016
Mainstay confirms its continued eligibility to the PEA-PME
07 Apr 2016
Mainstay Medical to present at Innovation in Medtech Dublin 2016 Conference
08 Feb 2016
Mainstay Medical Full Year 2015 Preliminary Results and Business Update
03 Feb 2016
Mainstay Medical Announces Date for 2015 Preliminary Results
04 Dec 2015
Additional Data Confirm Positive Results for Clinical Trial of ReActiv8
17 Nov 2015
Mainstay Medical to present at Stifel Nicolaus Healthcare Conference
09 Nov 2015
Mainstay Medical – November 2015 - Interim Management Statement
02 Nov 2015
Mainstay Medical Applies for CE Mark for ReActiv8
23 Sep 2015
Mainstay Medical to present at 3rd Annual MedTech & Digital Health Forum for Technology & Healthcare Innovation
31 Aug 2015
Positive Results for Mainstay Medical’s Clinical Trial of ReActiv8®
31 Aug 2015
Mainstay Medical Announces 2015 Half Year Financial Results
26 Aug 2015
Mainstay Medical Announces Additional US Patent Issued
25 Aug 2015
Mainstay Medical Announces Date for 2015 Half Year Results
24 Aug 2015
Mainstay Medical Secures $15M Debt Financing
15 Jul 2015
Mainstay Medical Announces Two Additional US Patents Issued
22 Jun 2015
Mainstay Medical Strengthens Board with New Independent Director
29 May 2015
Mainstay Medical Gains Approval to Start US Clinical Trial of ReActiv8
12 May 2015
Mainstay Medical – May 2015 - Interim Management Statement
08 May 2015
Mainstay Medical CEO to Present at the BioTrinity European Biopartnering and Investment Conference in London
07 Apr 2015
Mainstay Medical CEO to Present at Innovation in Medtech Conference
19 Mar 2015
Mainstay Medical Announces 2014 Financial Results
03 Mar 2015
Mainstay Medical Announces Date for 2014 Full Year Results
26 Jan 2015
Mainstay Medical Applies to Start US Clinical Trial of ReActiv8®
12 Jan 2015
Mainstay confirms its continued eligibility to the PEA-PME
05 Dec 2014
Mainstay Medical Achieves Quality System Certification
26 Nov 2014
Mainstay to Present at the Piper Jaffray Annual Healthcare Conference
06 Nov 2014
Mainstay Medical – November 2014 - Interim Management Statement
03 Nov 2014
Mainstay Medical to Present at the EMT Summit
28 Aug 2014
Mainstay Medical Announces 2014 Half Year Financial Results
22 Aug 2014
Mainstay Medical Announces Date for 2014 Half Year Results
28 Jul 2014
Mainstay Medical Expands Clinical Trial of ReActiv8®forPeople with Chronic Low Back Pain to the United Kingdom
07 Jul 2014
Mainstay Medical Announces Pre-IDE Submission for ReActiv8® to FDA
30 Jun 2014
Mainstay Medical Announces Expansion of Clinical Trial of ReActiv8® for People with Chronic Low Back Pain to Belgium
28 Apr 2014
Admission to Listing on Euronext Paris and the Irish Stock Exchange
10 Mar 2014
Mainstay Medical Begins Trial of ReActiv8
03 Feb 2014
Mainstay Medical Strengthens Board
31 Jan 2013
Mainstay Medical Appoints Oern R. Stuge MD as Chairman of the Board